Firebrick Pharma Limited · ASX:FRE
Firebrick Pharma — Investor Presentation (March 2026)
18 slides from Firebrick Pharma's investor presentation, Mar 4, 2026
Slide 1: Firebrick Investor Update Presentation (ASX announcement)
4 March 2026 ASX Announcement Firebrick Investor Update Presentation • Investor presentation with news about US Nasodine sales and plans for market and portfolio expansion • 275% growth reported in US winter sales and 168% increase in US customers; overall sales expected to double in calendar 2026 •
Slide 2: Investor Presentation
For personal use only Investor Presentation Peter Molloy Co-founder, CEO & Chairman MARCH 2026 ASX: FRE The world needs firebrickpharma.com
Slide 3: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation is provided for information purposes only. The information in this presentation is in a summary form, does not purport to be complete and is not intended to be relied upon as advice to investors or other persons. The information contained in this pre
Slide 4: Capital Structure
Capital Structure Financial Information (ASX: FRE) A$ Share Price & Volume Share price VWAP (1-28 Feb) $0.063 For personal use only $0.12 2,000 Shares on Issue 252.4m Market cap (approx.) $15.9m 1,800 $0.10 Cash balance (31 Dec 2025) $1.4m 1,600 Quarterly burn (31 Dec 2025) $0.6m 1,400 $0.08 Closing
Slide 5: Board and Senior Management
Board and Senior Management For personal use only Dr Peter Molloy Dr Stephen Goodall Rick Legleiter Al Moghaddam CEO, Chair & COO, Director & Founder Non-Executive Director Non-Executive Director Founder Currently recruiting Dr Simon Tucker Dr Monique Baldwin Kam Watson Head of Business Chief Scient
Slide 6: The Firebrick Mission
The Firebrick Mission To build a valuable OTC + HCP franchise under the “Nasodine” brand by: For personal use only Developing a Focusing the Nasodine Protecting our portfolio of innovative brand on a range of innovations with products based on the upper respiratory patents, clinical well-established
Slide 7: The world's first broad-spectrum antimicrobial nasal spray
Nasodine Nasal Spray The world’s first broad-spectrum antimicrobial nasal spray Large addressable market: For personal use only 17 billion URTIs each year globally RECOMMENDED USE: • Whenever exposed Nasodine breakthrough: first product that to people with targets the viral cause, not just symptoms
Slide 8: The world needs Nasodine
The world needs Nasodine Nasal Spray A remarkable innovation that will help humankind in many ways • We developed Nasodine as a treatment for the common cold and based on our 2019 For personal use only Phase III trial, it is effective if used in the first 24 hours after symptom onset. • Our 2023 Cov
Slide 9: Nasodine commercial timeline 2024
Nasodine commercial timeline 2024 Jan-Mar 2024: Apr 2024: Jun 2024: Aug 2024: Nov 2024: For personal use only GMP manufacturing Nasodine Nasal Spray Nasodine launched HCP sampling and HCP detailing of of Nasodine Nasal launched online in US online in Singapore via promotion at WONCA Nasodine Nasal S
Slide 10: Nasodine commercial timeline 2025
Nasodine commercial timeline 2025 Jan 2025: Feb 2025: Mar 2025: Oct 2025: For personal use only Start of retail pharmacy Nasodine available in Fiji Technology transfer and Unveiling of the first new distribution of Nasodine pharmacies and promoted GMP manufacturing of Nasodine product: through Guard
Slide 11: Current Market Portfolio
Current Market Portfolio We are at the early stage of the product life cycle Nasal Spray Throat Spray For personal use only Market Pop • 2025 was the first full year of (Mill) 2025 Launch Indication Revenue* Launch Indication marketing of the nasal spray in USA Singapore and US Nasal o Sales are sti
Slide 12: Strong growth of Nasodine in winter
Strong growth of Nasodine in winter Online sales are an early indicator of underlying growth and potential Online Unit Sales in Winter Period (3 Months) For personal use only 275% increase in US winter sales Dramatic increase in online sales of Nasodine Nasal Spray in the US winter 838 (Dec 2025-Feb
Slide 13: 2026: Growth in products and markets
2026: Growth in products and markets Nasodine Throat Spray For personal use only ● Singapore launch started in January 2026; online sales commence and local promotion to HCPs and hospitals; retail launch expected in H2 2026 ● Fiji launch began in February 2026, with focus on HCPs and pharmacy ● US o
Slide 14: Licensing model is scalable at low cost
Licensing model is scalable at low cost ● FRE creates innovative products, then offers exclusive licenses to distribution partners in each registerable country For personal use only ● License may include local manufacturing rights, e.g., the Philippines license. In other cases, manufacturing is cond
Slide 15: Catalysts for value growth
Catalysts for value growth In 2026, Firebrick expects: By end-2028, Firebrick expects: For personal use only • Ongoing sales growth in existing • At least 4 products in the 3 markets as Nasodine Nasal Spray enters its 3rd year; growth Nasodine portfolio accelerated by new products • Nasodine approve
Slide 16: Business model: FRE is not a biotech
Business model: FRE is not a “biotech” For personal use only Firebrick (FRE) is a All substantial Value creation is In each case, Currently we have 2 commercial-stage R&D is completed, driven by growth in realised value products in 2 small pharmaceutical so virtually no MARKETS and grows with market
Slide 17: Investor takeaways
Investor takeaways The world needs Nasodine: Nasodine Nasal Spray should be Firebrick is not a “biotech”; For personal use only 17 billion URTI p.a. and Nasodine the frontline nasal sanitizer in downside risk is low, cash burn Nasal Spray is the only product any future pandemic, for use by and fundi
Slide 18: For more information
For personal use only For more information: www.firebrickpharma.com ASX: FRE The world needs
Firebrick Pharma — Investor Presentation (March 2026) on 6ix